Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers.

Salazosulfapyridine (SASP) is widely used orally and rectally in the treatment of ulcerative colitis. SASP is mainly metabolized by hydrolysis and the main active metabolite, 5-aminosalicylic acid (5-ASA), has an antiinflammatory effect. In the present study, we prepared suppositories containing 6.5 mmol of SASP and an enema containing 6.5 mmol of 5-ASA. We measured the concentrations of SASP and its various metabolites, 5-ASA, sulfapyridine (SP), acetylated metabolite of SP (Ac-SP), and N-acetyl-5-ASA (Ac-5-ASA), in the serum and urine after a single administration of each preparation to healthy male volunteers. When the SASP suppository was administered, the maximum concentration (Cmax) of SASP and Ac-5-ASA was 2.5+/-0.4 and 0.5+/-0.2 microM and the time to Cmax (Tmax) was 5 and 12 h, respectively. The Cmax value of SP, which causes side effects, was one-half of that of the parent compound. No 5-ASA in the serum was observed. When the 5-ASA enema was administered, Cmax and Tmax values of 5-ASA and Ac-5-ASA were 5.8+/-2.0 and 13.3+/-3.6 microM and 1 and 7 h, respectively. The area under the serum concentration-time curve (AUC) of SASP was 27.4+/-4.8 microM x h, a finding similar to that of 5-ASA after the administration of the 5-ASA enema (29.4+/-11.1 microM x h). The percentage of urinary recovery of SASP 24 h after administration of the SASP suppository was approximately 0.2%. These results indicate that SASP administered rectally is almost completely hydrolyzed in the colon and that 5-ASA is partially absorbed from the small intestine in unchanged form. On the other hand, approximately 0.3% of 5-ASA was recovered in the urine in unchanged form after the administration of the 5-ASA enema, whereas the urinary recovery of Ac-5-ASA was more than 10%. The present findings suggest that 5-ASA has favorable absorptive properties and can be expected to have systemic action after rectal administration of a 5-ASA enema.

[1]  S. Targan,et al.  A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. , 1997, The American journal of gastroenterology.

[2]  U. Klotz,et al.  Clinical Pharmacokinetics of Sulphasalazine, Its Metabolites and Other Prodrugs of 5-Aminosalicylic Acid , 1985, Clinical pharmacokinetics.

[3]  M. Peppercorn.  Sulfasalazine: Pharmacology, Clinical Use, Toxicity, and Related New Drug Development , 1984 .

[4]  C. Hawkey,et al.  Inhibition of prostaglandin synthetase in human rectal mucosa. , 1983, Gut.

[5]  U. Klotz,et al.  Specific measurement of 5-aminosalicylic acid and its acetylated metabolite in human bile. , 1983, British journal of clinical pharmacology.

[6]  L. Aarons,et al.  A rapid method for the simultaneous determination of the major metabolites of sulphasalazine in plasma. , 1983, Journal of chromatography.

[7]  D. Jewell,et al.  Inhibition of leucocyte motility by drugs used in ulcerative colitis. , 1981, Gut.

[8]  J. V. van Tongeren,et al.  Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. , 1980, Gut.

[9]  J. Fordtran,et al.  Development of a lavage solution associated with minimal water and electrolyte absorption or secretion , 1980 .

[10]  J. McManus,et al.  Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. , 1973, The New England journal of medicine.

[11]  H. Schröder,et al.  Absorption, metabolism, and excretion of salicylazosulfapyridine in man , 1972, Clinical pharmacology and therapeutics.

[12]  M. Peppercorn,et al.  The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. , 1972, The Journal of pharmacology and experimental therapeutics.